BE1002159A5 - Adsorbats medicamenteux. - Google Patents

Adsorbats medicamenteux. Download PDF

Info

Publication number
BE1002159A5
BE1002159A5 BE8900501A BE8900501A BE1002159A5 BE 1002159 A5 BE1002159 A5 BE 1002159A5 BE 8900501 A BE8900501 A BE 8900501A BE 8900501 A BE8900501 A BE 8900501A BE 1002159 A5 BE1002159 A5 BE 1002159A5
Authority
BE
Belgium
Prior art keywords
adsorbates
medicinal
absorbates
aqueous
ranitidine
Prior art date
Application number
BE8900501A
Other languages
English (en)
French (fr)
Inventor
Stephen John Douglas
Fiona Ruth Bird
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888811167A external-priority patent/GB8811167D0/en
Priority claimed from GB888816185A external-priority patent/GB8816185D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002159A5 publication Critical patent/BE1002159A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
BE8900501A 1988-05-11 1989-05-10 Adsorbats medicamenteux. BE1002159A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888811167A GB8811167D0 (en) 1988-05-11 1988-05-11 Medicaments
GB888816185A GB8816185D0 (en) 1988-07-07 1988-07-07 Medicaments

Publications (1)

Publication Number Publication Date
BE1002159A5 true BE1002159A5 (fr) 1990-08-14

Family

ID=26293879

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900501A BE1002159A5 (fr) 1988-05-11 1989-05-10 Adsorbats medicamenteux.

Country Status (35)

Country Link
US (1) US5032393A (enExample)
JP (1) JP2944678B2 (enExample)
KR (1) KR890016968A (enExample)
CN (1) CN1027133C (enExample)
AT (1) AT401614B (enExample)
AU (1) AU624613B2 (enExample)
BE (1) BE1002159A5 (enExample)
CA (1) CA1337272C (enExample)
CH (1) CH679011A5 (enExample)
CY (1) CY1781A (enExample)
DE (1) DE3915347C2 (enExample)
DK (1) DK168934B1 (enExample)
ES (1) ES2011573A6 (enExample)
FI (1) FI92060C (enExample)
FR (1) FR2631232B1 (enExample)
GB (1) GB2218333B (enExample)
GR (1) GR1000358B (enExample)
HK (1) HK45094A (enExample)
HU (2) HU204994B (enExample)
IE (1) IE60722B1 (enExample)
IL (1) IL90245A (enExample)
IT (1) IT1232831B (enExample)
LU (1) LU87515A1 (enExample)
MX (1) MX173349B (enExample)
MY (1) MY104013A (enExample)
NL (1) NL8901188A (enExample)
NO (1) NO175131C (enExample)
NZ (1) NZ229064A (enExample)
PH (1) PH27612A (enExample)
PL (1) PL279377A1 (enExample)
PT (1) PT90523B (enExample)
RU (1) RU2033155C1 (enExample)
SE (1) SE508343C2 (enExample)
SG (1) SG48194G (enExample)
YU (1) YU47674B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
AU663695B2 (en) * 1990-12-21 1995-10-19 Richardson-Vicks Inc. Polyamine drug-resin complexes
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
ZA941544B (en) * 1993-03-05 1994-10-31 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
NO941358L (no) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
DK171127B1 (da) * 1994-04-22 1996-06-24 Gea Farmaceutisk Fabrik As Ranitidintablet med et hydroxypropylmethylcelluloseholdigt overtræk samt fremgangsmåde til at tilvejebringe dette overtræk
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
RU2131264C1 (ru) * 1996-06-04 1999-06-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоязвенное средство в виде таблеток и способ его получения
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
JP4346817B2 (ja) * 1997-09-30 2009-10-21 第一三共ヘルスケア株式会社 経口投与製剤
JP4283355B2 (ja) * 1997-11-10 2009-06-24 久光製薬株式会社 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
WO1999024072A1 (fr) * 1997-11-10 1999-05-20 Hisamitsu Pharmaceutical Co., Inc. Agent a liberation prolongee pour medicaments et composition pharmaceutique a liberation prolongee
RU2154469C2 (ru) * 1998-08-10 2000-08-20 Открытое акционерное общество фармацевтическая фирма "ЗДОРОВЬЕ" Способ получения таблеток ранитидина
WO2000010562A1 (fr) * 1998-08-18 2000-03-02 Leonidov Nikolai B Forme physiquement stable et amorphe aux rayons x de ranitidine d'hydrochlorure ayant une action anti-ulcere accrue, et procede de production
US6514492B1 (en) 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
JP2003504416A (ja) * 1999-07-14 2003-02-04 シェーリング−プラウ・リミテッド イオン交換樹脂を使用する経口キノロン液状製剤の味覚マスキング
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
ATE396746T1 (de) * 2002-01-18 2008-06-15 Rohm & Haas Verwendung eines resinats zur herstellung einer formulierung zur beendigung des rauchens
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
WO2007001300A1 (en) * 2005-06-28 2007-01-04 Ucb, S.A. Multiple active drug-resin conjugate
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20080226579A1 (en) * 2005-09-21 2008-09-18 Chong Kun Dang Pharmaceutical Corp. Novel Resinate Complex of S-Clopidogrel and Production Method Thereof
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
CN100411626C (zh) * 2006-08-28 2008-08-20 浙江大学 缓释型碘补充剂的制备方法
WO2008042218A1 (en) * 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
CN100450548C (zh) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 一种波拉克林树脂组合物的口腔贴片及其制备方法
EA021392B1 (ru) * 2007-10-11 2015-06-30 Филип Моррис Продактс С.А. Бездымный табачный продукт
WO2009102830A1 (en) * 2008-02-13 2009-08-20 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP5412966B2 (ja) * 2009-06-08 2014-02-12 ライオン株式会社 粒状製剤
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
CN102198118B (zh) * 2011-03-28 2012-08-29 于晓勇 一种治疗呕吐的口腔药物制剂及其制备方法
CN102138915A (zh) * 2011-03-28 2011-08-03 于晓勇 一种口服药物制剂及其制备方法
WO2014028610A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
CA3042466A1 (en) * 2016-11-01 2018-05-11 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form
WO2019207506A2 (en) 2018-04-27 2019-10-31 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2828207A (en) * 1955-11-14 1958-03-25 Du Pont Fortification of feed
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US2970053A (en) * 1958-10-28 1961-01-31 Pfizer & Co C Oleandomycin resin adsorbate
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
GB1180233A (en) * 1966-02-23 1970-02-04 Jean Astruc Modified Spiramycin
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
JPS5146154B2 (enExample) * 1972-05-11 1976-12-07
GB1462356A (en) * 1973-07-10 1977-01-26 Beecham Group Ltd Pharmaceutical compositions
JPS51125708A (en) * 1974-07-23 1976-11-02 Beecham Group Ltd Production of betaalactam antibiotic complex
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
DE3264782D1 (en) * 1981-10-16 1985-08-22 Sanol Arznei Schwarz Gmbh Medicinal formulation
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
JPS6369038A (ja) * 1986-09-10 1988-03-29 Canon Inc 光カ−ド記録媒体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Also Published As

Publication number Publication date
ES2011573A6 (es) 1990-01-16
GR1000358B (el) 1992-06-30
CN1037651A (zh) 1989-12-06
MY104013A (en) 1993-10-30
KR890016968A (ko) 1989-12-14
IE891527L (en) 1989-11-11
FI92060C (fi) 1994-09-26
GR890100314A (en) 1990-03-12
JPH02111719A (ja) 1990-04-24
GB2218333B (en) 1991-11-06
RU2033155C1 (ru) 1995-04-20
DE3915347A1 (de) 1989-11-16
DK229489D0 (da) 1989-05-10
JP2944678B2 (ja) 1999-09-06
PT90523A (pt) 1989-11-30
HK45094A (en) 1994-05-13
NL8901188A (nl) 1989-12-01
PL279377A1 (en) 1990-01-22
PH27612A (en) 1993-08-31
CY1781A (en) 1995-10-20
SE8901671L (sv) 1989-11-12
CH679011A5 (enExample) 1991-12-13
CA1337272C (en) 1995-10-10
CN1027133C (zh) 1994-12-28
IL90245A0 (en) 1989-12-15
SG48194G (en) 1994-11-25
LU87515A1 (fr) 1990-06-12
NZ229064A (en) 1991-12-23
DK229489A (da) 1989-11-12
MX15983A (es) 1993-10-01
FI892248L (fi) 1989-11-12
FR2631232A1 (fr) 1989-11-17
IE60722B1 (en) 1994-08-10
FR2631232B1 (fr) 1993-11-19
IT1232831B (it) 1992-03-05
ATA112089A (de) 1996-03-15
AU3461789A (en) 1989-11-16
NO175131C (no) 1994-09-07
YU97189A (en) 1990-06-30
SE508343C2 (sv) 1998-09-28
FI892248A0 (fi) 1989-05-10
YU47674B (sh) 1996-01-08
PT90523B (pt) 1994-10-31
DE3915347C2 (de) 1994-11-03
FI92060B (fi) 1994-06-15
US5032393A (en) 1991-07-16
NO891906D0 (no) 1989-05-10
GB2218333A (en) 1989-11-15
SE8901671D0 (sv) 1989-05-10
HU211592A9 (en) 1995-12-28
AU624613B2 (en) 1992-06-18
HU204994B (en) 1992-03-30
HUT50036A (en) 1989-12-28
MX173349B (es) 1994-01-22
DK168934B1 (da) 1994-07-11
NO175131B (no) 1994-05-30
AT401614B (de) 1996-10-25
IL90245A (en) 1994-04-12
GB8910706D0 (en) 1989-06-28
NO891906L (no) 1989-11-13
IT8947938A0 (it) 1989-05-10

Similar Documents

Publication Publication Date Title
BE1002159A5 (fr) Adsorbats medicamenteux.
ATE50433T1 (de) Pharmazeutische zusammensetzungen.
BE904547A (fr) Nouveaux medicaments a usage topique.
BE1002249A4 (fr) Compositions pharmaceutiques.
IT8220781A0 (it) Bifosfonati farmacologicamente attivi, procedimento per la loro preparazione e relative composizioni farmaceutiche.
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
IT1212778B (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
HUT77702A (hu) Vitamin és kalcium terápiás kombinációja egységes galenikus tabletta formában, eljárás előállítására és alkalmazása
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
SE8701087L (sv) Plackhemmande oral komposition
FR2578423B1 (fr) Composition pharmaceutique a base de gomme de guar pour la protection de la muqueuse oeso-gastro-duodenale
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
DK0437294T3 (da) Orale farmaceutiske præparater i enhedsdosisform
ATE187334T1 (de) Pharmazeutische zusammensetzung in form eines gels mit chondroitinsulfat in salzform zur oralen verabreichung
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2040239T3 (es) Procedimiento de preparacion de una composicion farmaceutica para la profilaxis y terapia de la ulcera gastrica.
FR2694558B1 (fr) Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
PT88145A (pt) Procede pour la preparation de composition pharmaceutique destinee a la prevention et au traitement des maladies bacteriennes ou virales
IT8621097A1 (it) Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
BE902055A (fr) Preparations pharmaceutiques.
AU570937B2 (en) Synergistic composition of hydroxyzine and salts thereof with nsaids
FR2759587B1 (fr) Composition pharmaceutique pour l'administration buccale de thiocolchicoside